Australia markets closed

Neurocrine Biosciences, Inc. (NBIX)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
139.40-1.11 (-0.79%)
At close: 04:00PM EDT
139.90 +0.50 (+0.36%)
After hours: 06:15PM EDT
Currency in USD

Valuation measures4

Market cap (intra-day) 14.03B
Enterprise value 13.33B
Trailing P/E 37.88
Forward P/E 28.33
PEG ratio (5-yr expected) 0.48
Price/sales (ttm)7.22
Price/book (mrq)5.88
Enterprise value/revenue 6.73
Enterprise value/EBITDA 26.82

Trading information

Stock price history

Beta (5Y monthly) 0.28
52-week change 354.70%
S&P500 52-week change 326.14%
52-week high 3148.37
52-week low 389.04
50-day moving average 3138.69
200-day moving average 3125.39

Share statistics

Avg vol (3-month) 3839.07k
Avg vol (10-day) 3659.78k
Shares outstanding 5100.64M
Implied shares outstanding 6101.44M
Float 899.41M
% held by insiders 11.00%
% held by institutions 195.97%
Shares short (30 Apr 2024) 41.83M
Short ratio (30 Apr 2024) 42.37
Short % of float (30 Apr 2024) 42.13%
Short % of shares outstanding (30 Apr 2024) 41.82%
Shares short (prior month 28 Mar 2024) 42.43M

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 429 Dec 1995
Last split factor 2N/A
Last split date 3N/A

Financial highlights

Fiscal year

Fiscal year ends 31 Dec 2023
Most-recent quarter (mrq)31 Mar 2024

Profitability

Profit margin 18.65%
Operating margin (ttm)20.43%

Management effectiveness

Return on assets (ttm)10.08%
Return on equity (ttm)18.16%

Income statement

Revenue (ttm)1.98B
Revenue per share (ttm)20.15
Quarterly revenue growth (yoy)22.60%
Gross profit (ttm)N/A
EBITDA 492.9M
Net income avi to common (ttm)369.7M
Diluted EPS (ttm)3.68
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)1.21B
Total cash per share (mrq)12.03
Total debt (mrq)410.7M
Total debt/equity (mrq)17.21%
Current ratio (mrq)2.52
Book value per share (mrq)23.72

Cash flow statement

Operating cash flow (ttm)645.4M
Levered free cash flow (ttm)719.32M